Genetics

Search documents
X @The Economist
The Economist· 2025-07-31 04:20
Genetically, the animal is about as far removed from a common nag as it is possible for a horse to be. The beast has never been tamed https://t.co/OMuFVhe8q4 ...
Why cousin marriage is a genetic gamble | Mohammed Jakir Hosen | TEDxCOU
TEDx Talks· 2025-07-29 14:49
[Music] Alam alaikum and very good morning everyone. I'm honored to be here and it is my real privilege to welcome you all to my talk. So today I'm going to talk about one of the most important public health issues that occur everywhere but nobody discussed that much that is the kajim.So think about these two rice. They fall in love and get married. Now they want to extend their family member.Sounds good, right. But problem is what I can say you with they the cousin or genetically related or bloodly related ...
X @The Economist
The Economist· 2025-07-26 08:40
Animal Genetics - The animal's genetic makeup is significantly different from that of a common horse [1] Animal Behavior - The animal has never been domesticated [1]
X @The Economist
The Economist· 2025-06-30 19:27
Scientists in China have presented the most complete attempt yet at making healthy, fertile mice from two sperm cells. Bipaternal human children, though, are still far away https://t.co/6pVZZVcFQy ...
X @The Economist
The Economist· 2025-06-30 15:00
Scientific Advancement - Mice with two fathers have successfully produced offspring using their own genetic material [1] Ethical Considerations - The technology is not expected to be applicable to humans in the near future [1]
23andMe (ME) Earnings Call Presentation
2025-06-25 11:31
Business Overview - 23andMe operates with two business verticals: Consumer and Research[11] - The Consumer business focuses on personalized health services, ancestry, and recurring subscription revenue[13] - The Research business leverages the world's largest re-contactable genetic and phenotypic data engine for data licensing, target discovery, and research services for pharma[15] - The company has genotyped over 15 million customers, with over 84% of customers opting-in to research, generating 4.8 billion phenotypic data points[17] Consumer Health - Genetics plays a role in 8 out of the 10 leading causes of death in the US[24] - 23andMe helps consumers identify their genetic risks, with over 28,000 customers identified with BRCA1/BRCA2 variants and over 4 million with a higher likelihood of type 2 diabetes[32] - 76% of customers report taking a positive health action after learning about their genetics[33] - 23andMe offers direct access to care with Lemonaid Health Telehealth Services, including access to GLP-1 drugs for weight loss in a number of states[43, 47] Research and AI - 23andMe has a large biobank with over 9 million research participants with ILD data sharing consent and over 5 million biobanked samples[65] - The company is pursuing multiple approaches to integrate Claims and EHR data into its existing data ecosystem, with over 5 million 23andMe customers having both Claims and EHR data[67, 71] - 23andMe is investing in AI to drive the next wave of insights and value-creation, leveraging its large-scale, relevant, and unique data[93] Financials - In FY2024, PGS revenue was $168 million with subscription revenue of $20 million[57] - For the three months ended December 31, 2024, Consumer Services revenue was $40 million (66% of total revenue) and Research Services revenue was $21 million (34% of total revenue)[104] - Total revenue for the three months ended December 31, 2024, was $60 million, compared to $45 million for the same period in FY2024[104] - Total revenue for FY2024 was $220 million, with Consumer Services accounting for $202 million (92%) and Research Services accounting for $17 million (8%)[104] - The company has $216 million in cash to support its plans for targeted investment in high ROI growth initiatives[103]
让科研人员不再做牛马!斯坦福大学华人团队打造首个通用生物医学AI智能体,从设计实验、数据分析到药物发现全自动搞定
生物世界· 2025-06-10 08:21AI Processing
编辑丨王多鱼 排版丨水成文 生物医学研究是增进人类对健康和疾病的理解、推动药物研发以及提升临床护理水平的基础。 然而,在生物医学实验室中,科研人员往往被复杂的实验方案、庞大的数据库、五花八门的分析工具以及不停更新的海量文献所淹没。生物医学研究日益受到这 些重复且分散的工作流程的制约,让科研人员疲于奔命, 严重减缓了科学发现的速度,限制了科学创新。这凸显了科学界对根本性新方法的迫切需求——一种能 够 有效扩展科学专业知识、简化研究工作流程,并充分释放生物医学研究潜力的全新路径。 2025 年 6 月 2 日, 斯坦福大学 黄柯鑫 、 Serena Zhang 、 王瀚宸 、 屈元昊 、 陆荧洲 等研究人员领衔的团队,联合 Genentech、Arc Institute、 加州大学 旧金山分校及 普林斯顿大学等 多个顶尖研究机构,发布了一款 通用生物医学 AI 智能体 —— Biomni ,该智能体能够自主完成横跨遗传学、基因组学、微生物 学、药理学和临床医学等多个生物医学分支领域的复杂研究任务 。 Biomni 的诞生标志着 AI 在生物医学研究中从"工具使用者"向"自主决策者"的跃迁 。通过将分散的科研资源整 ...
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
The Motley Fool· 2025-05-29 09:30
Core Insights - 23andMe filed for bankruptcy earlier this year due to unsustainable business losses despite the popularity of its DNA testing kits [1] - Regeneron Pharmaceuticals announced it would acquire substantially all of 23andMe's assets for $256 million, pending approval, with the deal expected to close in Q3 [2] - The acquisition provides Regeneron access to DNA data from 15 million customers, with 84% of them consenting to data use for research, presenting significant opportunities for drug development [5] Financial Overview - Regeneron's acquisition price of $256 million is modest compared to its nearly $3 billion free cash flow over the past four quarters, indicating financial stability [4] - Regeneron's first-quarter sales declined by 4% year over year, totaling just over $3 billion, with a 26% drop in sales of its leading drug, Eylea [7][8] - Despite recent stock performance challenges, with shares down 17% as of May 28, Regeneron trades at a modest 15 times trailing earnings compared to the S&P 500 average of just under 24 [12] Strategic Implications - The acquisition aligns with Regeneron's growth strategy focused on genetics, which is seen as critical for improving healthcare outcomes [6] - Regeneron has numerous therapeutic trials underway that could lead to future product launches, and the acquisition of 23andMe may enhance its drug candidate pipeline [9] - While Regeneron plans to continue offering 23andMe's consumer genome services, these services are not viewed as the primary reason for the acquisition and may eventually be discontinued if they hinder overall operations [11]